Fig. 1

Expression of CrebH mRNA and effects of CrebH ablation on the progression of IBD pathogenesis. A Expression of CrebH mRNA was determined in the colon and ileum by RT-qPCR (left). The specificity of the primer set for CrebH was validated by RT-qPCR in the liver from WT and CrebH^−/− mice (right). **P < 0.01 or ***P < 0.001. B Survival differences of WT and CrebH^−/− mice after 2.5% DSS were monitored daily. WT (n = 11) and CrebH^−/− (n = 10). C Bodyweight loss was estimated in the mouse groups; WT-con (n = 4, open square), CrebH^−/−-con (n = 4, blue square), WT-DSS, (n = 4, open circle), and CrebH^−/−-DSS (n = 4, red circle). D, E Hematocrit and colon length of WT (n = 4) and CrebH^−/− (n = 4) mice. F Liver histopathology of WT (n = 8) and CrebH^−/− (n = 7) mice were estimated by hematoxylin and eosin (H&E) staining (left) and scoring (right). The scale bar represents 200 μm. G The levels of IL-1β, IL-6, and TNFα were measured by qRT-PCR in the colon tissues from WT (blue) and CrebH^−/− (red) mice treated with 2.5% DSS for 7 days. Statistical analysis was performed using two-tailed Student’s t-test. Error bars represent the mean ± SEM